People with type 2 diabetes who have high blood glucose levels, low body weight, or a history of ketoacidosis may face a greater risk of developing the serious complication when treated with sodium-glucose co-transporter 2 inhibitors, according to a new report published on 1 September 2026.
Researchers flag a higher-risk group
The findings add to growing clinical attention around SGLT2 medicines, which are widely used in diabetes care but can, in rare cases, be associated with ketoacidosis. The report specifically identifies three factors that appear to raise risk: elevated blood glucose, low body weight, and a previous episode of ketoacidosis.
That combination could help clinicians identify which patients need closer monitoring before and during treatment. It also reinforces the importance of individual risk assessment rather than treating all patients with type 2 diabetes as a single group.
Why the warning matters for routine care
Ketoacidosis is a potentially life-threatening condition that requires urgent attention. For doctors and patients, the practical message is that symptoms and baseline risk should be considered carefully when SGLT2 therapy is prescribed. The new findings may be especially relevant in routine diabetes management, where treatment decisions often balance blood sugar control against safety concerns.
While the report does not suggest the drugs should be avoided broadly, it does indicate that some patients may need additional caution. In clinical settings, that could mean more careful education about warning signs and a lower threshold for review if symptoms develop.
What this could mean for UK diabetes practice
In the UK, diabetes treatment decisions are frequently shaped by the need to personalise therapy and reduce avoidable harm. A clearer understanding of which patients are most vulnerable to ketoacidosis may help support safer prescribing and more targeted follow-up.
The latest report is also a reminder that widely used medicines can carry different levels of risk depending on the person taking them. For patients already living with type 2 diabetes, that means conversations with healthcare professionals remain essential, particularly when there is a past history of ketoacidosis or other risk factors.
As clinical evidence continues to evolve, the focus is likely to remain on identifying patients who can benefit from SGLT2 treatment while minimising the chance of serious complications. The new findings add an important layer to that discussion.
Source: News-Medical medical condition news
Photo source: AI-generated or edited image
